Scintilla Pharmaceuticals, Inc. (“Scintilla”) is a subsidiary of Sorrento Therapeutics Inc. (the “Company”), a publicly traded company on the Nasdaq Stock Market (“SRNE”). Certain statements contained on this website or in other documents of the Company or statements by its management, may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same, partnering and collaboration opportunities, and Scintilla’s proposed acquisition of Semnur Pharmaceuticals, Inc. may differ from those set forth in the forward-looking statements. Any estimates regarding peak sales, market size and incidence have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size or incidence level estimates will prove accurate.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company’s Form 10-K, 10-Q and 8-K reports.